Please login to the form below
Pharmaceutical Market Europe (PME)
PME is a monthly print and digital title written by experienced journalists and high-profile pharma and healthcare experts. The magazine provides insights and offers solutions to the issues that keep industry leaders awake at night.
From the latest developments in cancer treatments and the strategies behind them to new marketing and commercialisation models and the regulations that underpin the fabric of the sector – PME's got it covered.
PME is a trusted source for decision makers and influencers in pharma and healthcare who, through the practical and accessible content, have the knowledge to tackle whatever comes their way.
J&J puts pressure on rivals with new Erleada okay in prostate cancer
FDA previously granted priority review in this indication
Bluebird Bio reveals further encouraging data for CALD gene therapy
Study shows continued benefit in treatment of rare disease
Takeda’s HAE drug Takhzyro backed by NICE
New treatment option for rare, hereditary disease
Distribution of Novartis’ generic Zantac halted due to carcinogen concerns
Ranitidine medicines found to contain cancer-causing substance
Articles
-
Encouraging signs in biomarker R&D The cancer immunotherapy firms ramping-up biomarker R&D
-
Trust: the ultimate elevatorBy Andreas Reinbolz, Daniel Schäfer and Ralf Steinmetz
-
The dawn of a new era in medical educationBy Annlouise Pendse
-
How can we realise the benefits of patient engagement?By Stephen O’Farrell and Nadine van Dongen
-
The power of high-value, highly relevant content to support clinical decisionsby Sandrine Veillet
Pharmaceutical Market Europe - September 2019
Patient vs Pharma, this is the situation which the industry dreads, but in 2019 has become a reality on several fronts: when patients see pharma not as a friend, but a foe.
Pharmaceutical Market Europe (PME) magazine is also available on the iPhone/iPad as a free app
Editor - Iona Everson
Have your say...
Subscribe
AZ shares spike on good second quarter led by cancer drugs
Soriot expecting no fewer than five of AZ’s new drugs to hit blockbuster status this year
'Nothing about us without us'
Why patient engagement is essential throughout the entire product life cycle
Featured jobs
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Events Executive
-
DOE
-
Senior Medical Writer
-
Competitive salary plus benefits
- Client Services Director- Flexible Working
-
Negotiable
-
Account Director – UK Office
-
Excellent salary and benefits
- Account Manager – Healthcare advertising
-
Salary TBC
Subscribe to our email news alerts
- Novartis eyes potential new indication for Cosentyx
- J&J's Tremfya filed for approval in US for psoriatic arthritis
- AbbVie/Allergan's merger faces public opposition
- Envision Pharma Group relocates to support expansion
- Biogen loses another pipeline drug to toxicity concerns
- AZ, Merck’s Lynparza scores market-expanding clinical success
- Report: Customer experience, shaping digital healthcare
- The benefits of uniting in a divergent environment
- Encouraging signs in biomarker R&D
- J&J puts pressure on rivals with new Erleada okay in prostate cancer
- Pharma exhibition stand design with added value
- Bluebird Bio reveals further encouraging data for CALD gene therapy
PMHub
Havas Life Medicom
We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...
Latest intelligence
- Report: Customer experience, shaping digital healthcare
- In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
- Encouraging signs in biomarker R&D
- The cancer immunotherapy firms ramping-up biomarker R&D...
- Programmatic methodology and why you should be using it
- What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...
Quick links
Infographics
